11 new development(s) in neoantigen vaccines today.
A custom mRNA vaccine is the first to succeed in a phase 3 trial. Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results come out Oct. 24…
Personalized mRNA vaccines that train the immune system to hunt a patient’s own tumor mutations are nearing approval, but, as Pharma Voice’s Alexandra Pecci reports, building them may prove harder than discovering them. Merck and Moderna’s melanoma vaccine, intismeran autogene, r…
Characterization of naturally processed MHC class I (MHC-I)-bound peptides is essential for defining allele-specific peptide-binding features and understanding the functional consequences of MHC-I polymorphism. However, immunopeptidome analyses of dog leukocyte antigen (DLA) clas…
Surveillance of individuals with Lynch syndrome (LS), who are carriers of heterozygous inactivating mismatch repair (MMR) gene mutations that predispose to colorectal cancer, enables the study of tumour-immune coevolution during tumour initiation. Somatic loss of MMR activity in …
Eric Lefkofsky, Founder and CEO of Tempus, shared Tempus AI’s post on LinkedIn, adding: “Sequencing is no longer just about matching a patient to an existing treatment – with individualized therapies, it’s becoming an integral part of the treatment itself. Tempus is at the forefr…
[ACTIVE_NOT_RECRUITING · PHASE1 · Dana-Farber Cancer Institute] This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC. Adjuvant treatment with the individualized, viral vector–based neoantigen vaccine TG4050 was safe and induced durable neoantigen-specific CD8-positiv…
Tempus AI (Nasdaq: TEM) announced an expanded, multi-year collaboration with Moderna (Nasdaq: MRNA) and Merck (NYSE: MRK) to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an investigational personalized cancer vaccine being developed in combinat…
[RECRUITING · PHASE1 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins] The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and…
Protein binding prediction is central to target identification, therapeutic binder design, and large scale screening, yet remains challenging because binding depends on sequence, three dimensional geometry, and global structural organization. Recent folding models such as AlphaFo…
Relevant work from earlier we're still surfacing — not today's news.